Kiniksa Historical Income Statement
| KNSA Stock | USD 20.58 0.83 3.88% |
Historical analysis of Kiniksa Pharmaceuticals income statement accounts such as Interest Expense of 2.4 M can show how well Kiniksa Pharmaceuticals performed in making a profits. Evaluating Kiniksa Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Kiniksa Pharmaceuticals's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Kiniksa Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Kiniksa Pharmaceuticals is a good buy for the upcoming year.
Kiniksa |
About Kiniksa Income Statement Analysis
Kiniksa Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Kiniksa Pharmaceuticals shareholders. The income statement also shows Kiniksa investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Kiniksa Pharmaceuticals Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Kiniksa Pharmaceuticals. It is also known as Kiniksa Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Kiniksa Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Kiniksa Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kiniksa Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Kiniksa Stock refer to our How to Trade Kiniksa Stock guide.At present, Kiniksa Pharmaceuticals' Net Interest Income is projected to increase significantly based on the last few years of reporting. The current year's Interest Income is expected to grow to about 1.6 M, whereas Tax Provision is forecasted to decline to (5.8 M).
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Income | 97K | 1.3M | 1.1M | 1.6M | Net Interest Income | 97K | 1.3M | 1.1M | 1.6M |
Kiniksa Pharmaceuticals income statement Correlations
Click cells to compare fundamentals
Kiniksa Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Kiniksa Pharmaceuticals income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Tax Provision | (2.0M) | 5.2M | 1.4M | (172.3M) | (5.6M) | (5.8M) | |
| Net Interest Income | 6.0M | 1.1M | 97K | 1.3M | 1.1M | 1.6M | |
| Interest Income | 6.0M | 1.1M | 97K | 1.3M | 1.1M | 1.6M | |
| Depreciation And Amortization | 2.1M | 2.4M | 2.4M | 4.2M | 2.3M | 1.9M | |
| Interest Expense | 8.1M | 3.5M | 2.5M | 1.3M | 1.4M | 2.4M | |
| Selling General Administrative | 35.0M | 45.3M | 85.9M | 98.0M | 119.9M | 125.9M | |
| Gross Profit | (3.3M) | (3.8M) | 29.4M | 173.2M | 213.7M | 224.4M | |
| Other Operating Expenses | 170.0M | 157.4M | 195.2M | 210.4M | 295.5M | 168.6M | |
| Operating Income | (170.0M) | (157.4M) | (156.6M) | 7.4M | (25.2M) | (26.5M) | |
| Net Income From Continuing Ops | (161.9M) | (161.4M) | (157.9M) | 183.4M | (6.7M) | (7.0M) | |
| Ebit | (170.0M) | (157.4M) | (156.6M) | 5.6M | (25.2M) | (26.5M) | |
| Research Development | 135.0M | 112.0M | 99.3M | 65.5M | 76.1M | 89.1M | |
| Ebitda | (167.9M) | (155.0M) | (154.3M) | 9.8M | (22.9M) | (24.0M) | |
| Cost Of Revenue | 3.3M | 3.8M | 9.1M | 47.0M | 56.5M | 59.4M | |
| Total Operating Expenses | 170.0M | 157.4M | 186.1M | 163.4M | 238.9M | 153.1M | |
| Income Before Tax | (163.9M) | (156.2M) | (156.5M) | 11.0M | (16.7M) | (17.5M) | |
| Total Other Income Expense Net | 6.0M | 1.1M | 97K | 1.3M | 8.5M | 9.0M | |
| Net Income Applicable To Common Shares | (161.9M) | (161.4M) | (157.9M) | 183.4M | 210.9M | 221.4M | |
| Net Income | (161.9M) | (161.4M) | (157.9M) | 183.4M | 14.1M | 14.8M | |
| Income Tax Expense | (2.0M) | 5.2M | 1.4M | (172.3M) | (30.7M) | (32.3M) | |
| Reconciled Depreciation | 2.1M | 2.4M | 2.4M | 2.4M | 2.4M | 1.9M | |
| Non Operating Income Net Other | 6.0M | 1.1M | 97K | 1.3M | 1.1M | 2.1M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Kiniksa Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kiniksa Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kiniksa Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kiniksa Pharmaceuticals Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kiniksa Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Kiniksa Stock refer to our How to Trade Kiniksa Stock guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kiniksa Pharmaceuticals. If investors know Kiniksa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kiniksa Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 5.5 | Earnings Share (0.12) | Revenue Per Share 5.415 | Quarterly Revenue Growth 0.674 | Return On Assets (0.03) |
The market value of Kiniksa Pharmaceuticals is measured differently than its book value, which is the value of Kiniksa that is recorded on the company's balance sheet. Investors also form their own opinion of Kiniksa Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Kiniksa Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kiniksa Pharmaceuticals' market value can be influenced by many factors that don't directly affect Kiniksa Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kiniksa Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Kiniksa Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kiniksa Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.